Menú
Menú
Menú
We share our journey of innovation and collaboration, bringing to light the impactful research and developments from our dedicated team. Keep an eye here for the latest coverage and breakthroughs that are setting new benchmarks in medical science.
Nanoligent is proud to announce its active participation in the Arquídemes Accelerator, a groundbreaking initiative in collaboration with Santander Bank (Universidades section). This first edition of the program is dedicated to fostering the growth of emerging companies, mainly spin-offs from the University.
Nanoligent Joins Arquímedes Accelerator for Intensive Growth Program
This media highlights the following:
«The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
Nanoligent raises 1 million euros for its cancer treatment using nanotechnology – El Periódico (spanish)
The ONCO Emergence forum took place last June 21-22th at the Fira Gran Via (Barcelona). It is a networking conference focused on setting up transnational collaboration projects in the field of oncology and promotes interaction among research institutes, companies and medical facilities.
Nanoligent awarded 1st prize in ONCO Emergence Forum Barcelona 2018
This newspaper highlights the following:
«Researchers from the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona (UAB), from the Research Institute of the Hospital de la Santa Creu i Sant Pau, and from the CIBER of Bioengineering, Biomaterials, and Nanomedicine have launched a ‘spin-off’ that aims to create a drug that eliminates cancer stem cells.»
Nanoligent develops a new anticancer drug – La Vanguardia (spanish)
This media highlights the following:
«The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
Nanoligent desarrolla nuevo fármaco anticanceroso – UAB (catalan)
Financiado por la Unión Europea – NextGenerationEU. Sin embargo, los puntos de vista y las opiniones expresadas son únicamente los del autor o autores y no reflejan necesariamente los de la Unión Europea o la Comisión Europea. Ni la Unión Europea ni la Comisión Europea pueden ser consideradas responsables de las mismas.